R&D channel feed

FDA+ roundup: FDA con­tin­ues to loosen stan­dard of ev­i­dence for nov­el drug ap­provals — JA­MA re­search let­ter

Last year
FDA+

Terns Phar­ma­ceu­ti­cals touts mid-stage suc­cess for NASH drug, stock falls

Last year

Gates-backed study of faster tu­ber­cu­lo­sis drug treat­ments kicks off in South Africa

Last year

No­var­tis flex­es PhI­II win for oral BTK in­hibitor in chron­ic spon­ta­neous ur­ticaria

Last year

De­nali, Take­da scrap PhI Alzheimer's drug due to safe­ty sig­nals, 'rapid­ly evolv­ing' land­scape

Last year

Oculis eye drop se­cures an­oth­er late-stage win, this time in post-cataract surgery in­flam­ma­tion and pain 

Last year

Up­dat­ed: Bay­er cuts PhII or­phan drug as it ups R&D spend­ing, ques­tions swirl around new CEO’s next moves

Last year

Up­dat­ed: No­vo Nordisk's semaglu­tide in­jec­tion re­duces car­dio­vas­cu­lar events by 20% in vast SE­LECT tri­al

Last year

Ar­cus de­pri­or­i­tizes Gilead-part­nered drug in prostate can­cer, the lat­est hic­cup in $1.6B col­lab­o­ra­tion

Last year

Nek­tar says Eli Lil­ly mis­cal­cu­lat­ed da­ta in eczema tri­al be­fore break­ing off rezpeg part­ner­ship

Last year

Ac­er­a­gen to pull out of Nas­daq and liq­ui­date as­sets, end­ing tu­mul­tuous jour­ney for Idera Phar­ma

Last year
Pharma

Bavar­i­an Nordic makes plans to sub­mit chikun­gun­ya vac­cine for ap­proval af­ter sec­ond pos­i­tive PhI­II tri­al read­out

Last year

Up­dat­ed: FDA ap­proves Bio­gen and Sage's pill for post­par­tum de­pres­sion, but re­jects use in ma­jor de­pres­sion

Last year
Pharma

Born out of Omega push for pan­dem­ic treat­ments, Aeri­um Ther­a­peu­tics en­ters long Covid R&D

Last year
Startups
Coronavirus

As Ver­tex’s piv­otal pain read­out looms, non-opi­oid drug de­vel­op­ment faces a reck­on­ing

Last year
In Focus

Two deaths halt Re­gen­eron’s prostate can­cer bis­pe­cif­ic an­ti­body tri­al as it looks at tweak­ing com­bo plans

Last year

Am­gen touts two can­cer study wins with DLL3, Lumakras amid sec­ond-quar­ter earn­ings up­date

Last year

J&J sets its sights on par­ents — and chil­dren’s vi­sion — in new back-to-school so­cial me­dia cam­paign

Last year

Agios to take over Al­ny­lam’s pre­clin­i­cal siR­NA blood dis­or­der as­set in a deal worth $147.5M

Last year
Deals

Hous­ton biotech Ar­a­vive re­ports PhI­II ovar­i­an can­cer fail, shares nose­dive

Last year

Sarep­ta dos­es first pa­tient with Duchenne gene ther­a­py fol­low­ing ac­cel­er­at­ed ap­proval

Last year
Cell/Gene Tx

A broad new idea for treat­ing vi­ral in­fec­tions: blow­ing up their pro­tec­tive mem­branes

Last year
Discovery

Ver­tex dos­es first pa­tient with next type 1 di­a­betes cell ther­a­py pro­gram, while padding its cof­fers with strong Q2

Last year

Failed tri­als for 16 IGF-1R in­hibitors and $1.6B lat­er: Time for bet­ter pre­clin­i­cal mod­els?

Last year
First page Previous page 76777879808182 Next page Last page
A service from the Financial Times